Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. (NYSE: BAX) is a global medtech company whose news flow reflects its focus on connected care technologies, medical devices and advanced injectable therapies. On this page, readers can follow company announcements that illustrate how Baxter’s products and partnerships intersect with hospital operations, nursing workflows and patient safety.
Recent Baxter news highlights the launch of the Dynamo Series smart stretcher, designed for emergency departments, perioperative environments and patient transport services. Baxter reports that the Dynamo Series is intended to reduce the need for patient transfers, support a range of procedures in-stretcher, and incorporate technologies such as SafeView+ visual cues, bed exit alarms and optional connectivity to EMRs and nurse call systems to help prevent patient falls and support care teams.
Other updates include a multi-year strategic partnership with MUSC Health focused on integrating connected care technologies at the bedside. Baxter and MUSC Health describe objectives such as standardizing and simplifying bedside technologies, reducing documentation time, streamlining communication, improving nurse satisfaction and retention, and using real-time insights and advanced monitoring to enhance quality and safety outcomes.
Baxter also issues news on its infusion therapy portfolio, such as real-world data presented with The University of Texas Medical Branch on the Spectrum IQ large volume infusion pumps. These analyses examine how smart pump integration with electronic medical records may affect patient safety alerts, infusion programming time and clinician workload.
In addition, investors can find announcements on capital allocation decisions, including tender offers for senior notes, new note issuances and dividend declarations, as well as philanthropic news from the Baxter Foundation, such as grants to support STEM education through the Baxter Center for Science Education. Bookmark this page to access Baxter’s latest product, partnership, financial and community impact news in one place.
Baxter International Inc. (NYSE:BAX) reported Q1 2021 results, with worldwide sales of approximately $2.9 billion, up 5%. U.S. sales decreased by 3% to $1.2 billion, while international sales rose 11% to $1.8 billion. Net income was $298 million, down 9%. The company emphasizes ongoing growth driven by its Acute Therapies and BioPharma Solutions units, supporting COVID-19 efforts. Notable achievements include FDA clearances for new products and strategic acquisitions to enhance its pharmaceuticals portfolio. For 2021, Baxter expects earnings of $2.85 to $2.93 per share and sales growth of 8-9%.
Baxter International Inc. (NYSE:BAX) has achieved recognition on the Global Inclusion Index across 11 countries, highlighting its commitment to diversity and inclusion. The countries recognized include Brazil, China, France, and others. This accolade, presented by Seramount, evaluates corporate efforts in promoting women and creating inclusive cultures. Baxter's leaders focus on advancing women into leadership roles, particularly in Europe. The company has received multiple diversity awards, consistently achieving high scores on equality indices, emphasizing its ongoing commitment to an inclusive workplace.
Baxter International Inc. (NYSE:BAX) has received a €1.5 million R&D grant from Germany's BMBF to develop a new technology platform for extracorporeal blood purification therapies. This initiative aims to enhance the selective removal of pathogenic substances while preserving essential blood components. Collaborating with Rapp Polymere GmbH, the project will focus on modifying biomaterials and coatings. Baxter aims to advance treatment options for patients suffering from acute conditions, maintaining its leadership in multi-organ support therapies.
Baxter International (NYSE:BAX) will present at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 8:45 a.m. ET. CFO Jay Saccaro will lead the presentation, which can be accessed via a live webcast on Baxter's official website. The replay will be available until August 11, 2021. Baxter, with over 85 years in healthcare, delivers a wide range of critical care and surgical products globally, impacting millions of patients and caregivers each day.
Baxter International (NYSE:BAX) announces its 2021 Annual Meeting will be virtual due to COVID-19 safety concerns. Scheduled for May 4, 2021, at 9 a.m. CT, the meeting will begin online access at 8:30 a.m. Shareholders can vote in advance or electronically during the meeting. Questions for management can be submitted via proxyvote.com until May 3, 2021, or live during the event. A shareholder list will be available online. Baxter continues to support critical healthcare innovations worldwide.
Summary not available.
Baxter International Inc. (NYSE:BAX) has announced a conference call scheduled for April 29, 2021, at 7:30 a.m. Central Time to discuss its first-quarter 2021 financial results. Participants can pre-register via a provided link to receive call information. The call will also be accessible through Baxter's website.
Baxter, a leader in medical products, serves millions of patients globally with a diverse portfolio aimed at critical care and innovation in healthcare solutions.
Baxter International Inc. (NYSE:BAX) has received FDA clearance for its AK 98 dialysis machine, which aims to provide a portable and user-friendly option for administering hemodialysis (HD) treatments. The AK 98 features encrypted connectivity, auto alert resolution, and an intuitive interface to streamline workflows in chronic and hospital care settings. This platform has been established in over 90 countries and will be available in the U.S. soon. The system is designed to enhance treatment efficiency and patient management.
Baxter International will participate in the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, with CFO Jay Saccaro presenting at 10:40 a.m. ET. The presentation will be accessible via a live webcast at www.baxter.com, and available for replay until September 13, 2021. Baxter is a leader in medical products, providing critical care, nutrition, and renal products globally for over 85 years.
Baxter International and Moderna have entered an agreement for Baxter's BioPharma Solutions to manufacture and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 Vaccine in 2021. The manufacturing will occur in Bloomington, Indiana, utilizing Baxter's 20 years of experience in vaccine production. This partnership aims to enhance Moderna's manufacturing capacity in the U.S., allowing for the expedited rollout of the vaccine to meet public health needs.